Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TSHA - Taysha Gene Therapies, Inc.

IEX Last Trade
1.855
0.015   0.809%

Share volume: 17,890
Last Updated: Thu 26 Dec 2024 08:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.84
0.02
0.82%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 18%
Dept financing 24%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.09%
1 Month
-36.86%
3 Months
-11.90%
6 Months
-9.31%
1 Year
9.47%
2 Year
-3.14%
Key data
Stock price
$1.86
P/E Ratio 
-4.02
DAY RANGE
$1.76 - $1.84
EPS 
-$0.57
52 WEEK RANGE
$1.36 - $4.31
52 WEEK CHANGE
$3.93
MARKET CAP 
459.073 M
YIELD 
N/A
SHARES OUTSTANDING 
204.943 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
2.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,877,494
AVERAGE 30 VOLUME 
$4,060,870
Company detail
CEO: R. A. Session
Region: US
Website: tayshagtx.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Taysha Gene Therapies, Inc. focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas.

Recent news